Bio-Business in Brief: The Debate Over Biosimilars

Current cience, 98, 1575-1578, 2010

Posted: 28 Jan 2016 Last revised: 26 Feb 2016

See all articles by Gayatri Saberwal

Gayatri Saberwal

Institute of Bioinformatics and Applied Biotechnology

Date Written: June 25, 2010

Abstract

Biosimilars are the subject of much debate: should they be allowed or not? Some of the issues are discussed here. Also those approved in Europe and India are listed.

(Article freely downloadable from the journal website.)

Keywords: Biotechnology, biosimilars, drug company, follow on biologics, pharma industry

JEL Classification: I10, O32, O51, O52, O53

Suggested Citation

Saberwal, Gayatri, Bio-Business in Brief: The Debate Over Biosimilars (June 25, 2010). Current cience, 98, 1575-1578, 2010, Available at SSRN: https://ssrn.com/abstract=2723893

Gayatri Saberwal (Contact Author)

Institute of Bioinformatics and Applied Biotechnology ( email )

Biotech Park
Electronics City Phase 1
Bengaluru, Karnataka 560100
India

Do you have negative results from your research you’d like to share?

Paper statistics

Abstract Views
245
PlumX Metrics